Rivas Medical Weight Loss

Rivas Medical Weight Loss operates as a physician-supervised weight management clinic in Frederick, Maryland, under the direction of Dr. Tomas Rivas. The practice focuses exclusively on medical weight loss through GLP-1 receptor agonist peptide therapy, offering both semaglutide and tirzepatide as primary treatment modalities. With a 5.0-star rating across 380 Google reviews, the clinic has established a reputation for structured, protocol-driven weight management programs that combine pharmaceutical intervention with metabolic assessment. Patients access care through in-person visits at the Frederick location or via telehealth consultations available to residents of Maryland, Virginia, and Florida.

The clinic's treatment approach centers on two FDA-approved GLP-1 medications: semaglutide, which mimics the glucagon-like peptide-1 hormone to regulate appetite and insulin secretion, and tirzepatide, a dual GIP/GLP-1 receptor agonist that targets both glucose-dependent insulinotropic polypeptide and GLP-1 pathways for enhanced metabolic effect. Dr. Rivas develops individualized protocols following comprehensive laboratory analysis that evaluates metabolic markers, hormone levels, and organ function to determine appropriate peptide selection and dosing schedules. Body composition testing provides baseline measurements of fat mass, lean tissue, and metabolic rate, allowing the clinic to track physiological changes beyond standard scale weight and adjust treatment parameters based on objective data rather than subjective reporting alone.

Dr. Tomas Rivas brings physician-level oversight to every patient program, conducting initial consultations that include medical history review, contraindication screening, and goal-setting discussions. His approach emphasizes patient education regarding GLP-1 mechanism of action, expected timeline for appetite suppression and weight reduction, potential side effects such as nausea or gastrointestinal adjustment, and the importance of protein intake and resistance activity to preserve lean muscle during caloric deficit. The clinic's protocols include regular follow-up intervals to monitor tolerance, adjust dosing as patients progress through titration schedules, and address questions that arise during treatment—a factor frequently mentioned in patient feedback regarding the accessibility of the medical team.

Patients beginning treatment at Rivas Medical Weight Loss undergo an intake process that establishes baseline metrics through laboratory work and body composition analysis before receiving their first peptide prescription. The clinic provides clear instructions on subcutaneous injection technique for patients self-administering semaglutide or tirzepatide at home, along with guidance on injection site rotation and proper medication storage. Follow-up visits occur at intervals determined by individual response and titration schedule, typically ranging from monthly to quarterly depending on treatment phase. The Frederick office accommodates patients who prefer in-person monitoring, while the telehealth platform extends access to patients across Maryland, Virginia, and Florida who meet eligibility criteria for remote peptide therapy management.

Rivas Medical Weight Loss distinguishes itself through its singular focus on GLP-1 peptide therapy rather than offering a broad menu of weight loss modalities, allowing the practice to develop deep expertise in semaglutide and tirzepatide protocols. The clinic's consistent 5.0-star rating across a substantial review volume reflects systematic attention to patient communication, with feedback emphasizing the team's responsiveness to questions, thoroughness in explaining treatment plans, and ability to create individualized approaches that account for each patient's metabolic profile and weight loss objectives. For Frederick-area residents and telehealth-eligible patients in the Mid-Atlantic and Florida regions seeking physician-supervised GLP-1 therapy, the clinic offers a structured medical weight loss program grounded in laboratory-guided peptide selection and ongoing metabolic monitoring.